Development of Ulvan-Containing Liposomes as Antibacterial Drug Delivery Platforms
Source abstract
Abstract
Liposomes, due to their safety profile and targeting ability, are among the most studied nanocarriers as antimicrobial delivery systems. However, due to lack of stability and the non-specific interaction of liposomes with cells and proteins, their use is relatively limited. Aiming to overcome these drawbacks, it was envisaged that incorporation of ulvan, a bioactive marine sulfated polysaccharide isolated from green algae, in liposomes could improve their physicochemical properties and overall stability. Thus, we initially studied the interactions of ulvan with neutral, negatively, and positively charged lipids using Differential Scanning Calorimetry and subsequently, based on the obtained results, we prepared the respective ulvan–containing neutral and charged liposomes, where ulvan interacts with both lipid chains and polar groups in the liposomal bilayer. In a further step, we entrapped in the liposomes fusidic acid, used as a model antibacterial drug, and proceeded with the evaluation of their antibacterial activity against Staphylococcus aureus. The physicochemical properties (size and ζ-potential), stability, morphology, and entrapment efficiency of the prepared liposomal formulations were determined.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Seaweed-derived Bioactive Compounds · Chemical and Physical Studies · Nanocomposite Films for Food Packaging
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Section of Pharmacognosy and Chemistry of Natural Products, Department of Pharmacy, National and Kapodistrian University of Athens, Panepistimiopolis Zografou, 15771 Athens, Greece
Section of Pharmaceutical Technology, Department of Pharmacy, National and Kapodistrian University of Athens, Panepistimiopolis Zografou, 15771 Athens, Greece
Funding
European Union
References (67)
Show source-provided references
1. Anti-MRSA malleable liposomes carrying chloramphenicol for ameliorating hair follicle targeting10.2147/IJN.S147226 ↗
2. Engineering liposomes for drug delivery: Progress and problems10.1016/S0167-7799(00)89017-4 ↗
3. Liposomal antibiotics for the treatment of infectious diseases10.1517/17425247.2013.822860 ↗
4. Lipid and polymer nanoparticles for drug delivery to bacterial biofilms10.1016/j.jconrel.2014.03.055 ↗
5. Rai, M., and Kon, K. (2015). Nanocarriers against bacterial biofilms: Current status and future perspectives. Nanotechnology in Diagnosis, Treatment and Prophylaxis of Infectious Diseases, Elsevier.
6. Rukavina, Z., and Vanić, Ž. (2016). Current trends in development of liposomes for targeting bacterial biofilms. Pharmaceutics, 8.10.3390/pharmaceutics8020018 ↗
7. Demonstration of a fusion mechanism between a fluid bactericidal liposomal formulation and bacterial cells10.1016/S0005-2736(99)00217-5 ↗
8. Liposomal drug delivery systems: From concept to clinical applications10.1016/j.addr.2012.09.037 ↗
9. Polysaccharide-decorated nanoparticles10.1016/j.ejpb.2004.02.016 ↗
10. Dumitriu, S. (2001). Polysaccharides as biomaterials. Polymeric Biomaterials, Marcel Dekker.10.1201/9780203904671.pt1 ↗
11. Self-assembled hydrogel nanoparticles from curdlan derivatives: Characterization, anti-cancer drug release and interaction with hepatoma cell line (HepG2)10.1016/S0168-3659(00)00256-X ↗
12. Therapeutic importance of sulfated polysaccharides from seaweeds: Updating the recent findings10.1007/s13205-012-0061-9 ↗
13. Re-evaluating the importance of carbohydrates as regenerative biomaterials10.1093/rb/rby023 ↗
14. Recent advances in natural polymer-based drug delivery systems10.1016/j.reactfunctpolym.2020.104501 ↗
15. Sterically stabilized liposomes10.1016/0304-4157(92)90038-C ↗
16. The use of glycolipids and hydrophilic polymers in avoiding rapid uptake of liposomes by the mononuclear phagocyte system10.1016/0169-409X(94)90016-7 ↗
17. Hyaluronic acid-modified bioadhesive liposomes as local drug depots: Effects of cellular and fluid dynamics on liposome retention at target sites10.1006/abbi.1997.0356 ↗
18. Cationic liposome–hyaluronic acid hybrid nanoparticles for intranasal vaccination with subunit antigens10.1016/j.jconrel.2015.04.010 ↗
19. Liposomes coated with chemically modified dextrans interact with human endothelial cells10.1002/(SICI)1097-4636(199902)44:2<140::AID-JBM3>3.0.CO;2-5 ↗
20. Interactions of functionalized dextran-coated liposomes with vascular smooth muscle cells10.1016/S0168-3659(99)00240-0 ↗
21. Polysaccharide coated liposomes for oral immunization—Development and characterization10.1016/S0378-5173(00)00442-7 ↗
22. Development of chitosan-coated liposome for pulmonary delivery of N-acetylcysteine10.1016/j.ijbiomac.2019.11.190 ↗
23. Effective mucoadhesive liposomal delivery system for risedronate: Preparation and in vitro/in vivo characterization
24. Chitosan-coated liposomes for topical vaginal therapy: Assuring localized drug effect10.1016/j.ijpharm.2014.06.016 ↗
25. Andersen, T., Mishchenko, E., Eide Flaten, G., Ericson Sollid, J.U., Mattsson, S., Tho, I., and Škalko-Basnet, N. (2017). Chitosan-based nanomedicine to fight genital Candida infections: Chitosomes. Mar. Drugs, 15.10.3390/md15030064 ↗
26. Exploring anti-MRSA activity of chitosan-coated liposomal dicloxacillin10.1016/j.mimet.2018.11.015 ↗
27. Control in mineralization by the polysaccharide-coated liposome via the counter-diffusion of ions10.1021/cm201211n ↗
28. Structure and function properties of ulvan, a polysaccharide from green seaweeds10.1021/bm061185q ↗
29. Impact of stabilization treatments of the green seaweed Ulva rotundata (Chlorophyta) on the extraction yield, the physico-chemical and rheological properties of ulvan10.1016/j.carbpol.2008.02.020 ↗
30. Extraction and physicochemical characterization of a versatile biodegradable polysaccharide obtained from green algae10.1016/j.carres.2010.07.039 ↗
31. Ulvan: A systematic review of extraction, composition and function10.1016/j.algal.2019.101422 ↗
32. Pignatello, R. (2011). Ulvan: A versatile platform of biomaterials from renewable resources. Biomaterials-Physics and Chemistry, InTech.10.5772/914 ↗
33. Biological activities and potential health benefits of sulfated polysaccharides derived from marine algae10.1016/j.carbpol.2010.10.062 ↗
34. Sulfated polysaccharides as bioactive agents from marine algae10.1016/j.ijbiomac.2013.08.036 ↗
35. Ulvan, a bioactive marine sulphated polysaccharide as a key constituent of hybrid biomaterials: A review10.1016/j.carbpol.2019.04.074 ↗
36. PDLLA enriched with ulvan particles as a novel 3D porous scaffold targeted for bone engineering10.1016/j.supflu.2012.02.023 ↗
37. Processing of degradable ulvan 3D porous structures for biomedical applications10.1002/jbm.a.34403 ↗
38. Carboxymethylation of ulvan and chitosan and their use as polymeric components of bone cements10.1016/j.actbio.2013.06.036 ↗
39. Biofunctionalization of ulvan scaffolds for bone tissue engineering10.1021/am404912c ↗
40. Ulvan as a new type of biomaterial from renewable resources: Functionalization and hydrogel preparation10.1002/macp.200900562 ↗
41. Design, preparation and characterization of ulvan based thermosensitive hydrogels10.1016/j.carbpol.2015.09.068 ↗
42. Tziveleka, L.-A., Sapalidis, A., Kikionis, S., Aggelidou, E., Demiri, E., Kritis, A., Ioannou, E., and Roussis, V. (2020). Hybrid sponge-like scaffolds based on ulvan and gelatin: Design, characterization and evaluation of their potential use in bone tissue engineering. Materials, 13.10.3390/ma13071763 ↗
43. Ulvan and ulvan/chitosan polyelectrolyte nanofibrous membranes as a potential substrate material for the cultivation of osteoblasts10.1016/j.carbpol.2012.04.045 ↗
44. Ulvan-chitosan polyelectrolyte complexes as matrices for enzyme induced biomimetic mineralization10.1016/j.carbpol.2017.11.016 ↗
45. Marine sulfated polysaccharides as versatile polyelectrolytes for the development of drug delivery nanoplatforms: Complexation of ulvan with lysozyme10.1016/j.ijbiomac.2018.06.050 ↗
46. Processing ulvan into 2D structures: Crosslinked ulvan membranes as new biomaterials for drug delivery applications10.1016/j.ijpharm.2012.01.021 ↗
47. Nanofibers based on polysaccharides from the green seaweed Ulva rigida10.1016/j.carbpol.2010.12.075 ↗
48. Electrospun biocomposite nanofibers of ulvan/PCL and ulvan/PEO10.1002/app.42153 ↗
49. Ulvan/gelatin-based nanofibrous patches as a promising treatment for burn wounds10.1016/j.jddst.2022.103535 ↗
50. Liposomal fusidic acid as a potential delivery system: A new paradigm in the treatment of chronic plaque psoriasis10.3109/10717544.2015.1110845 ↗
51. Disulfides with anti-inflammatory activity from the brown alga Dictyopteris membranacea10.1021/acs.jnatprod.5b01031 ↗
52. Phases and phase transitions of the phosphatidylcholines10.1016/S0304-4157(98)00006-9 ↗
53. Preparation and thermal behavior of liposomal nanoparticles incorporating bioactive labdane epimers10.1166/asl.2012.3277 ↗
54. Evolution and development of model membranes for physicochemical and functional studies of the membrane lateral heterogeneity10.1016/j.bbamem.2018.03.010 ↗
55. Properties of mixed DOTAP-DPPC bilayer membranes as reported by differential scanning calorimetry and dynamic light scattering measurements10.1021/jp071722g ↗
56. Physico-chemical stability of colloidal lipid particles10.1016/S0142-9612(03)00331-4 ↗
57. Zeta potential: A case study of cationic, anionic and neutral liposomes10.1007/s00216-017-0527-z ↗
58. Does sucrose influence the properties of DMPC vesicles?10.1016/S0009-3084(02)00140-8 ↗
59. Chitosan in mucoadhesive drug delivery: Focus on local vaginal therapy10.3390/md13010222 ↗
60. Performance of fusidic acid (CEM-102) susceptibility testing reagents: Broth microdilution, disk diffusion, and as Etest methods applied to Staphylococcus aureus10.1128/JCM.01829-09 ↗
61. Interaction of vesicles: Adhesion, fusion and multicompartment systems formation10.1002/cbic.201000614 ↗
62. Effect of zeta potential value on bacterial behavior during electrophoretic separation10.1002/elps.200900559 ↗
63. Mapping fusogenicity of ciprofloxacin-loaded liposomes with bacterial cells10.1208/s12249-019-1381-4 ↗
64. Enhanced activity of antibiotics by liposomal drug delivery
65. Biofilm penetration, triggered release and in vivo activity of inhaled liposomal amikacin in chronic Pseudomonas aeruginosa lung infections10.1093/jac/dkn059 ↗
66. The interaction of phospholipid liposomes with bacteria and their use in the delivery of bactericides10.3109/10611869708995855 ↗
67. The targeting of phospholipid liposomes to bacteria10.1016/0005-2736(94)90295-X ↗